Please login to the form below

Not currently logged in
Email:
Password:

ViiV

This page shows the latest ViiV news and features for those working in and with pharma, biotech and healthcare.

ViiV’s two-drug HIV combo backed by CHMP

ViiV’s two-drug HIV combo backed by CHMP

ViiV’ s two-drug HIV combo backed by CHMP. The committee also backs two biosimilar medicines. ... ViiV Healthcare’s dual HIV therapy Juluca has been given a green light by the EMA’s Committee for Medicinal Products for Human Use (CHMP), setting up

Latest news

  • Gilead says switching studies back new HIV therapy Biktarvy Gilead says switching studies back new HIV therapy Biktarvy

    share for ViiV, so Gilead will have to pull out all the stops to build momentum behind its new drug. ... GSK alleges that Gilead’s HIV integrase inhibitor bictegravir infringes on patents held by ViiV on dolutegravir, and it wants to receive royalties

  • Gilead’s triple HIV drug approval prompts GSK lawsuit Gilead’s triple HIV drug approval prompts GSK lawsuit

    Gilead’ s triple HIV drug approval prompts GSK lawsuit. ViiV claims bictegravir infringes its patent estate. ... ViiV says Biktarvy infringes its US and Canadian patents covering “dolutegravir and many other compounds that include dolutegravir’s

  • ViiV starts trial of HIV-preventing injections for women ViiV starts trial of HIV-preventing injections for women

    ViiV starts trial of HIV-preventing injections for women. Cabotegravir could provide a new way for women to protect themselves. ... to protect themselves from HIV, ”commented ViiV ’s chief scientific and medical officer John Pottage.

  • GSK’s ViiV gets US okay for two-drug HIV regimen GSK’s ViiV gets US okay for two-drug HIV regimen

    GSK’ s ViiV gets US okay for two-drug HIV regimen. Juluca is a combination of ViiV’s Tivicay and Janssen’s Edurant. ... The FDA has approved a dual therapy for HIV from GlaxoSmithKline’s ViiV joint venture with Johnson &Johnson, which is expected

  • Janssen wins European approval for Symtuza Janssen wins European approval for Symtuza

    Janssen can now market Symtuza in all countries in the European Union and the European Economic Area, where it will be vying to compete with therapies from GlaxoSmithKline's ViiV unit.

More from news
Approximately 28 fully matching, plus 60 partially matching documents found.

Latest Intelligence

  • Stronger together Stronger together

    The top-down approach has certainly been in evidence at ViiV, the joint venture between GlaxoSmithKline, Pfizer and Shionogi, as its CEO Dominique Limet told the eyeforpharma audience. “ ... This year's survey of European patient groups marked the

  • Deal Watch December 2015 Deal Watch December 2015

    2, 075. BMS (HIV business). GSK (ViiV). Acquisition - asset. Acquisition of HIV product pipeline from BMS incl.

  • Understanding the patient ecosystem Understanding the patient ecosystem

    The continued success of the ViiV pharma group, which has three times now been deemed the most reputable and engaged pharma firm in the eyes of patient charities, also highlights how

  • Choices, choices: the rapidly evolving HIV treatment landscape Choices, choices: the rapidly evolving HIV treatment landscape

    With the recent launch of Triumeq from ViiV – whose owner, GSK, brought the first HIV treatment to market in the late 1980s – this looks set to change. ... Viiv's Triumeq is now following a similar pattern. Although it gained EU approval in September

  • Pharma deals during October 2012 Pharma deals during October 2012

    The first is the revised deal between ViiV Healthcare (the speciality HIV company formed by GSK and Pfizer in 2009) and Shionogi. ... Under the new agreement, ViiV Healthcare will acquire the exclusive global rights to the assets in the Shionogi-ViiV

More from intelligence
Approximately 2 fully matching, plus 5 partially matching documents found.

Latest appointments

  • GSK's Deborah Waterhouse to take over from ViiV' Dominique Limet GSK's Deborah Waterhouse to take over from ViiV' Dominique Limet

    GSK's Deborah Waterhouse to take over from ViiV' Dominique Limet. She will become CEO designate at the HIV-focused firm in January. ... He said: “ Establishing and then leading ViiV Healthcare for the past seven years has been an incredible honour and

  • Phil Golz appointed commercial director at HealthUnlocked Phil Golz appointed commercial director at HealthUnlocked

    Phil Golz appointed commercial director at HealthUnlocked. Moves from ViiV Healthcare to join the socialnetwork for health. ... He joins the company from ViiV Healthcare, where he was executive director, and prior to that he served as head of commercial

More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 14 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Streaming Well

Streaming Well is a healthcare focused, award-winning video production company which operates in the US and Europe....

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics